NCT04169893View on ClinicalTrials.gov

A Phase I Study of TS-142 in Healthy Participants (Single Doses)

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 17, 2015

Primary Completion Date

February 6, 2016

Study Completion Date

February 6, 2016

Conditions
Healthy Volunteer
Interventions
DRUG

Placebo (fasting)

Participants will receive placebo once in fasting condition

DRUG

Placebo (feeding)

Participants will receive placebo once after meal condition

DRUG

1 mg of TS-142

Participants will receive 1 mg of TS-142 once in fasting condition

DRUG

3 mg of TS-142

Participants will receive 3 mg of TS-142 once in fasting condition

DRUG

10 mg of TS-142 (fasting)

Participants will receive 10 mg of TS-142 once in fasting condition

DRUG

10 mg of TS-142 (feeding)

Participants will receive 10 mg of TS-142 once after meal condition

DRUG

30 mg of TS-142

Participants will receive 30 mg of TS-142 once in fasting condition

Trial Locations (1)

Unknown

The medical facility selected by Taisho Pharmaceutical Co., Ltd, Fukuoka

All Listed Sponsors
lead

Taisho Pharmaceutical Co., Ltd.

INDUSTRY

NCT04169893 - A Phase I Study of TS-142 in Healthy Participants (Single Doses) | Biotech Hunter | Biotech Hunter